See more : BLACKROCK CDR (CAD HEDGED) (BLK.NE) Income Statement Analysis – Financial Results
Complete financial analysis of Intellipharmaceutics International Inc. (IPCI.TO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intellipharmaceutics International Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Sincere Watch (Hong Kong) Limited (0444.HK) Income Statement Analysis – Financial Results
- Harbin Dongan Auto Engine Co.,Ltd (600178.SS) Income Statement Analysis – Financial Results
- Zhengzhou Tiamaes Technology Co., Ltd (300807.SZ) Income Statement Analysis – Financial Results
- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) Income Statement Analysis – Financial Results
- MEDIPOST Co., Ltd. (078160.KQ) Income Statement Analysis – Financial Results
Intellipharmaceutics International Inc. (IPCI.TO)
About Intellipharmaceutics International Inc.
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.73K | 0.00 | 1.40M | 3.48M | 1.71M | 5.50M | 2.25M | 4.09M | 8.77M | 1.53M | 107.09K | 501.81K | 1.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 999.82 | 100.06K | 99.84K | 70.27K | 74.21K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 33.07K | 124.87K | 704.01K | 8.17M | 7.25M | 8.02M | 5.08M | 5.99M | 5.13M | 4.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -212.98K | -200.12K | -99.84K | 0.00 | 0.00 |
| Gross Profit | 65.73K | 0.00 | 1.40M | 3.45M | 1.59M | 4.80M | -5.92M | -3.15M | 749.49K | -3.55M | -5.89M | -4.62M | -3.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 213.98K | 300.18K | 199.68K | 70.27K | 74.21K |
| Gross Profit Ratio | 100.00% | 0.00% | 100.00% | 99.05% | 92.71% | 87.21% | -263.45% | -77.04% | 8.55% | -232.33% | -5,495.63% | -921.42% | -210.63% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 21,402.15% | 300.00% | 200.00% | 100.00% | 100.00% |
| Research & Development | 2.15M | 2.66M | 3.52M | 6.61M | 10.83M | 9.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.08M | 12.03M | 28.67M | 61.15M | 43.62M | 16.74M | 8.10M | 5.85M | 3.98M | 3.20M | 3.00M | 3.65M | 2.23M |
| General & Administrative | 0.00 | 1.21M | 2.08M | 0.00 | 0.00 | 0.00 | 3.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.61M | 3.36M | 2.20M | 1.70M | 1.83M | 1.26M |
| Selling & Marketing | 0.00 | 39.75K | 65.76K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 561.05K | 1.25M | 2.15M | 4.17M | 3.48M | 3.29M | 3.55M | 3.58M | 3.90M | 2.87M | 3.67M | 2.93M | 2.70M | 6.52M | 14.25M | 16.86M | 18.94M | 13.35M | 7.90M | 4.99M | 4.61M | 3.36M | 2.20M | 1.70M | 1.83M | 1.26M |
| Other Expenses | 206.06K | 261.53K | 415.38K | 505.80K | 610.38K | 506.96K | 385.21K | 377.85K | 381.39K | 396.81K | 452.30K | 227.46K | 242.78K | 0.00 | 154.12K | 2.19M | 348.98K | 6.98M | 856.24K | -1.00K | 1.00K | 212.98K | 200.12K | 199.68K | 0.00 | 0.00 |
| Operating Expenses | 2.92M | 4.17M | 6.08M | 11.28M | 14.91M | 13.07M | 3.93M | 3.96M | 4.28M | 3.27M | 4.12M | 3.15M | 2.94M | 13.60M | 26.44M | 47.72M | 80.44M | 63.95M | 25.49M | 13.09M | 10.46M | 7.55M | 5.60M | 4.89M | 5.48M | 3.49M |
| Cost & Expenses | 2.92M | 4.17M | 6.08M | 11.32M | 15.04M | 13.77M | 12.10M | 11.21M | 12.30M | 8.35M | 10.12M | 8.28M | 7.48M | 13.60M | 26.44M | 47.72M | 80.44M | 63.95M | 25.49M | 13.09M | 10.46M | 7.34M | 5.40M | 4.79M | 5.48M | 3.49M |
| Interest Income | 291.62K | 549.30K | 969.65K | 13.54K | 227.00 | 15.04K | 207.00 | 1.51K | 4.90K | 2.84K | 20.69K | 60.79K | 27.00K | 0.00 | 1.31M | 1.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 291.62K | 549.30K | 969.65K | 247.52K | 255.23K | 526.60K | 270.24K | 256.63K | 339.45K | 429.95K | 63.41K | 2.44M | 98.44K | -413.08K | 3.63M | 11.32M | -1.07M | 5.81M | -25.01K | -623.92K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 206.06K | 261.53K | 2.92M | 520.22K | 612.74K | 520.84K | 385.21K | 377.85K | 381.39K | 396.81K | 452.30K | 227.46K | 242.78K | 174.73K | 656.53K | 2.87M | 853.51K | 390.18K | 303.08K | 240.97K | 219.02K | 212.98K | 200.12K | 199.68K | 0.00 | 0.00 |
| EBITDA | -2.64M | -3.91M | -1.76M | -7.31M | -12.89M | -7.73M | -9.47M | -6.73M | -3.15M | -6.42M | -13.47M | -12.83M | -6.10M | -13.84M | -22.15M | -33.53M | -80.66M | -57.75M | -25.22M | -13.47M | -11.55M | -7.97M | -5.10M | -4.49M | -5.41M | -3.41M |
| EBITDA Ratio | -4,023.32% | 0.00% | -125.79% | -210.16% | -752.49% | -140.43% | -421.26% | -164.50% | -35.88% | -420.24% | -12,581.29% | -2,555.95% | -417.94% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,155,450.73% | -797,380.59% | -5,099.98% | -4,499.99% | -7,700.00% | -4,600.00% |
| Operating Income | -2.85M | -4.17M | -4.68M | -7.83M | -13.33M | -8.27M | -9.85M | -7.11M | -3.53M | -6.82M | -10.12M | -7.78M | -6.05M | -13.60M | -26.44M | -47.72M | -80.44M | -63.95M | -25.49M | -13.09M | -10.46M | -7.34M | -5.30M | -4.69M | -5.41M | -3.41M |
| Operating Income Ratio | -4,336.82% | 0.00% | -333.80% | -225.11% | -778.07% | -150.17% | -438.41% | -173.76% | -40.28% | -446.40% | -9,447.17% | -1,549.72% | -414.72% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,046,045.90% | -733,774.14% | -5,299.98% | -4,699.99% | -7,700.00% | -4,600.00% |
| Total Other Income/Expenses | -36.55K | -1.09M | 1.32M | -255.06K | -421.21K | -591.66K | -292.50K | -322.93K | -323.66K | -4.68M | 3.92M | 5.28M | 326.25K | 413.08K | -3.63M | -11.32M | 1.07M | -5.81M | 25.01K | 623.92K | 1.31M | 848.94K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -2.89M | -5.26M | -3.36M | -8.09M | -13.75M | -8.86M | -10.14M | -7.44M | -3.86M | -11.50M | -6.20M | -2.50M | -5.73M | -13.19M | -30.07M | -59.05M | -79.37M | -69.77M | -25.47M | -12.47M | -9.15M | -6.49M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -4,392.43% | 0.00% | -239.61% | -232.44% | -802.66% | -160.91% | -451.43% | -181.65% | -43.97% | -752.55% | -5,790.66% | -498.17% | -392.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -914,740.11% | -648,865.54% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 5.34K | -114.19K | 32.83K | -5.36K | -8.59K | 80.09K | 22.47K | 67.81K | -10.90K | 4.25M | -7.85M | -10.61M | -679.50K | -1.07M | 5.95M | 21.73M | -1.85M | 4.65M | -906.25K | -1.25M | -2.63M | -1.70M | 100.06K | 99.84K | 70.27K | 74.21K |
| Net Income | -2.89M | -5.15M | -3.39M | -8.08M | -13.75M | -8.86M | -10.14M | -7.44M | -3.86M | -11.50M | -6.14M | -4.88M | -5.76M | -12.94M | -28.76M | -58.13M | -79.67M | -62.79M | -24.61M | -12.47M | -9.15M | -6.49M | -5.40M | -4.79M | -5.48M | -3.49M |
| Net Income Ratio | -4,400.55% | 0.00% | -241.95% | -232.28% | -802.66% | -160.91% | -451.43% | -181.65% | -43.97% | -752.55% | -5,730.51% | -972.53% | -394.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -914,740.18% | -648,965.54% | -5,399.98% | -4,799.99% | -7,800.00% | -4,700.00% |
| EPS | -0.09 | -0.17 | -0.14 | -0.37 | -2.89 | -2.86 | -3.80 | -3.13 | -1.67 | -5.84 | -3.56 | -3.25 | -5.28 | -5.78 | -14.59 | -66.11 | -100.44 | -91.35 | -40.00 | -25.78 | -20.38 | -14.85 | -18.48 | -18.79 | -26.04 | -27.05 |
| EPS Diluted | -0.09 | -0.17 | -0.14 | -0.37 | -2.89 | -2.86 | -3.80 | -3.13 | -1.67 | -5.84 | -3.56 | -3.25 | -5.28 | -5.78 | -14.59 | -66.11 | -100.44 | -91.35 | -40.00 | -25.78 | -20.38 | -14.85 | -18.48 | -18.79 | -25.91 | -27.05 |
| Weighted Avg Shares Out | 33.09M | 29.43M | 23.56M | 21.58M | 4.76M | 3.10M | 2.67M | 2.38M | 2.31M | 1.97M | 1.73M | 1.50M | 1.09M | 2.24M | 1.97M | 879.29K | 793.22K | 687.29K | 615.38K | 483.46K | 448.93K | 436.82K | 292.38K | 255.00K | 210.53K | 128.95K |
| Weighted Avg Shares Out (Dil) | 33.09M | 29.43M | 23.56M | 21.58M | 4.76M | 3.10M | 2.67M | 2.38M | 2.31M | 1.97M | 1.73M | 1.50M | 1.09M | 2.24M | 1.97M | 879.29K | 793.22K | 687.29K | 615.38K | 483.46K | 448.93K | 436.82K | 292.38K | 255.00K | 211.54K | 128.95K |
Source: https://incomestatements.info
Category: Stock Reports